title: Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy.
abstract: Ipilimumab, monoclonal antibody against cytotoxic T-lymphocyte antigen-4 and, radiotherapy are commonly used to treat unresectable and metastatic melanoma. As a result of upregulation of immune system with ipilimumab, many immune-related adverse effects, such as dermatitis, colitis, hepatitis, and hypophysitis, have been previously reported in literature. Typically, these effects are treated with high-dose steroids and mostly heal up. Here, we report a case who was receiving radiotherapy due to metastatic malignant melanoma with atypical generalized rash, which was enlarged with concurrent ipilimumab treatment.
authors.affiliation: Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey drangelkarakurt@hotmail.com.
authors.forename: Melek Karakurt
authors.initials: MK
authors.lastname: Eryılmaz
authors.affiliation: Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
authors.forename: Hasan
authors.initials: H
authors.lastname: Mutlu
authors.affiliation: Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
authors.forename: Derya Kıvrak
authors.initials: DK
authors.lastname: Salim
authors.affiliation: Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
authors.forename: Fatma Yalçın
authors.initials: FY
authors.lastname: Musri
authors.affiliation: Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
authors.forename: Deniz
authors.initials: D
authors.lastname: Tural
authors.affiliation: Department of Pathology, Akdeniz University School of Medicine, Antalya, Turkey.
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Başsorgun
authors.affiliation: Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
authors.forename: Hasan Şenol
authors.initials: HŞ
authors.lastname: Coşkun
mesh_terms: D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000074324:Ipilimumab / Q000009:adverse effects* / Q000627:therapeutic use; D008545:Melanoma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D008875:Middle Aged; D011855:Radiodermatitis / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis*; D012720:Severity of Illness Index; D012878:Skin Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy
chemical_list: D000074322:Antineoplastic Agents, Immunological; D000074324:Ipilimumab
keywords: Melanoma; cytotoxic T-lymphocyte antigen-4; dermatitis; ipilimumab; radiotherapy